Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma

被引：44

作者：

Ladanyi, Marc ^{[1
,2
]}

Vega, Francisco Sanchez ^{[3
]}

Zauderer, Marjorie ^{[4
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10065 USA

[3] Mem Sloan Kettering Canc Ctr, Computat Biol Program, 1275 York Ave, New York, NY 10065 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA

来源：

GENOME MEDICINE | 2019年 / 11卷 / 1期

关键词：

CELLS;

D O I：

10.1186/s13073-019-0631-0

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future trials. A new study finds that loss of the deubiquitinase BAP1 in PeM correlates with an inflammatory tumor microenvironment, suggesting that BAP1 status might identify PeM, and possibly PlM, patients who would benefit from ICI therapy.

引用

页数：3

共 50 条

[1] Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
Marc Ladanyi
Francisco Sanchez Vega
Marjorie Zauderer
Genome Medicine, 11
[2] BAP1 Deficiency Inflames the TME & is a Candidate Biomarker for Improved Immunotherapy in Malignant Pleural Mesothelioma
Xu, D.
Gao, Y.
Yang, H.
Marti, T. M.
Losmanova, T.
Dorn, P.
Shu, Y.
Peng, R.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S164 - S165
[3] BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma
Xu, Duo
Gao, Yanyun
Yang, Haitang
Spils, Marc
Marti, Thomas M.
Losmanova, Tereza
Su, Min
Wang, Wenxiang
Zhou, Qinghua
Dorn, Patrick
Shu, Yongqian
Peng, Ren-Wang
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (05):
[4] Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy
Ghafoor, Azam
Hassan, Raffit
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (07) : 862 - 864
[5] BAP1 mutation in mesothelioma and "BAP1 Cancer Syndrome"
Nasu, Masaki
Napolitano, Andrea
Pastorino, Sandra
Tanji, Mika
Flores, Erin
Baumann, Francine
Powers, Amy
Gaudino, Giovanni
Pass, Harvey I.
Yang, Haining
Carbone, Michele
CANCER RESEARCH, 2014, 74 (19)
[6] LOSS OF BAP1 FUNCTION LEADS TO TRAIL SENSITIVITY IN MESOTHELIOMA
Kumar, N.
Kolluri, K. K.
Alifrangis, C.
Ishii, Y.
Price, S.
Michaut, M.
Williams, S.
Barthorpe, S.
Lightfoot, H.
Busacca, S.
Sharkey, A.
Yuan, Z.
Sage, E. K.
Vallath, S.
Le Quesne, J.
Tice, D. A.
Alrifai, D.
von Karstedt, S.
Montinaro, A.
Guppy, N.
Waller, D. A.
Nakas, A.
Good, R.
Holmes, A.
Walczak, H.
Fennell, D. A.
Garnett, M.
Iorio, F.
Wessels, L.
McDermott, U.
Janes, S. M.
THORAX, 2018, 73 : A1 - A1
[7] Loss of expression of BAP1 predicts longer survival in mesothelioma
Farzin, Mahtab
Toon, Christopher W.
Clarkson, Adele
Sioson, Loretta
Watson, Nicole
Andrici, Juliana
Gill, Anthony J.
PATHOLOGY, 2015, 47 (04) : 302 - 307
[8] BAP1 loss in the diagnosis of malignant mesothelioma; review of a regional mesothelioma MDT
Mcdill, H.
Dipper, A.
Bhatt, N.
Clive, A.
Maskell, N.
Bibby, A.
EUROPEAN RESPIRATORY JOURNAL, 2022, 60
[9] Familial mesothelioma: Beyond BAP1
Cheung, Mitchell
Ohar, Jill A.
Howard, Suzanne E.
Howard, Timothy D.
Hesdorffer, Mary
Testa, Joseph R.
CANCER RESEARCH, 2018, 78 (13)
[10] BAP1 loss in malignant mesothelioma: distribution according the histological subtype
Martin Lopez, J.
Martin Acosta, P.
Salas Anton, C.
VIRCHOWS ARCHIV, 2020, 477 : S121 - S122

← 1 2 3 4 5 →